Genetic polymorphisms as prognostic factors for recurrent kidney stones: A systematic review and meta-analysis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
03
2021
accepted:
22
04
2021
entrez:
6
5
2021
pubmed:
7
5
2021
medline:
21
10
2021
Statut:
epublish
Résumé
Genetic polymorphisms have been suggested as risk factors affecting the occurrence and recurrence of kidney stones, although findings regarding the latter remain inconclusive. We performed this systematic review and meta-analysis to clarify the associations between genetic polymorphisms and recurrent kidney stones. PubMed, SCOPUS, EMBASE, and Cochrane Library databases were searched through May 28th, 2020 to identify eligible studies. The Quality in prognostic studies (QUIPS) tool was used to evaluate bias risk. Allelic frequencies and different inheritance models were assessed. All analyses were performed using Review manager 5.4. A total of 14 studies were included for meta-analysis, assessing urokinase (ApaL1) and vitamin D receptor (VDR) (ApaI, BsmI, FokI, and TaqI) gene polymorphisms. The ApaLI polymorphism demonstrated protective association in the recessive model [odds ratio (OR) 0.45, P < 0.01] albeit higher risk among Caucasians in the heterozygous model (OR 16.03, P < 0.01). The VDR-ApaI polymorphism showed protective association in the dominant model (OR 0.60, P < 0.01). Among Asians, the VDR-FokI polymorphism recessive model showed significant positive association (OR 1.70, P < 0.01) and the VDR-TaqI polymorphism heterozygous model exhibited protective association (OR 0.72, P < 0.01). The VDR-BsmI polymorphism was not significantly associated with recurrent kidney stones in any model. Urokinase-ApaLI (recessive model), VDR-ApaI (dominant model), and VDR-TaqI (heterozygous model) polymorphisms were associated with decreased recurrent kidney stone risk whereas urokinase-ApaLI (heterozygous model) and VDR-FokI polymorphisms were associated with increased risk among Caucasians and Asians, respectively. These findings will assist in identifying individuals at risk of kidney stone recurrence.
Identifiants
pubmed: 33956883
doi: 10.1371/journal.pone.0251235
pii: PONE-D-21-08368
pmc: PMC8101940
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0251235Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nephrol Dial Transplant. 2004 Sep;19(9):2259-65
pubmed: 15213319
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Asian J Urol. 2018 Oct;5(4):205-214
pubmed: 30364478
PLoS Med. 2014 Oct 14;11(10):e1001744
pubmed: 25314315
Urol Res. 2012 Feb;40(1):35-40
pubmed: 21814771
J Urol. 2011 May;185(5):1742-6
pubmed: 21420116
Gene. 2004 Sep 1;338(2):143-56
pubmed: 15315818
Transl Psychiatry. 2020 Jun 30;10(1):209
pubmed: 32606422
BJU Int. 2007 Jun;99(6):1534-8
pubmed: 17419705
Can Urol Assoc J. 2016 Nov-Dec;10(11-12):E347-E358
pubmed: 28096919
Urol Res. 2012 Aug;40(4):277-84
pubmed: 22116536
Urol Res. 2001 Dec;29(6):412-6
pubmed: 11828995
Urol Int. 2014;92(3):356-62
pubmed: 24296906
Scand J Urol Nephrol. 2010 Dec;44(6):406-12
pubmed: 20602573
J Urol. 2007 Jun;177(6):2361-5
pubmed: 17509359
Diagn Progn Res. 2019 Mar 7;3:5
pubmed: 31093575
Am J Epidemiol. 2009 Feb 15;169(4):505-14
pubmed: 19126586
J Intern Med. 2003 Feb;253(2):194-200
pubmed: 12542560
N Engl J Med. 1993 Mar 25;328(12):833-8
pubmed: 8441427
Scand J Urol Nephrol. 2010 Feb;44(1):20-6
pubmed: 20017708
Hum Mol Genet. 2002 Oct 1;11(20):2417-23
pubmed: 12351577
Urolithiasis. 2016 Apr;44(2):109-15
pubmed: 26275878
Eur J Nutr. 2021 Mar 4;:
pubmed: 33661376
Urol Res. 2003 Jul;31(3):218-22
pubmed: 12719950
BJU Int. 2001 Sep;88(4):432-6
pubmed: 11564035
Urol Int. 2003;70(4):278-81
pubmed: 12740491
Int Urol Nephrol. 2008;40(3):563-8
pubmed: 18240004
Eur Urol. 2001 Jun;39(6):716-9
pubmed: 11464063
Urol Res. 2001 Oct;29(5):321-4
pubmed: 11762793
Clin Cases Miner Bone Metab. 2008 May;5(2):101-6
pubmed: 22460989
Biomed Rep. 2014 Jan;2(1):69-74
pubmed: 24649071
Indian J Clin Biochem. 2008 Apr;23(2):106-16
pubmed: 23105735
Gene. 2012 Dec 15;511(2):127-30
pubmed: 23046575
Eur Urol. 2012 Jul;62(1):160-5
pubmed: 22498635
Urology. 2002 Mar;59(3):458-61
pubmed: 11880102
Sci Rep. 2019 Nov 21;9(1):17296
pubmed: 31754202
J Endourol. 2006 Feb;20(2):157-60
pubmed: 16509805
Mediators Inflamm. 2015;2015:375427
pubmed: 26089600
Ann Intern Med. 1989 Dec 15;111(12):1006-9
pubmed: 2688503
Urology. 2004 Oct;64(4):833-8
pubmed: 15491743
Circulation. 2007 Sep 18;116(12):1356-66
pubmed: 17846284
Mol Ther Nucleic Acids. 2020 Jun 5;20:13-24
pubmed: 32171170
Nephrol Dial Transplant. 2012 Jan;27(1):210-8
pubmed: 21652546
J Nephrol. 2017 Jun;30(3):411-418
pubmed: 27639591
Biomed Res Int. 2014;2014:397826
pubmed: 24800221
Ann Intern Med. 2013 Feb 19;158(4):280-6
pubmed: 23420236
Int J Urol. 2007 Apr;14(4):344-9
pubmed: 17470169
Urol Res. 2001 Apr;29(2):98-101
pubmed: 11396736
Int J Urol. 2007 Dec;14(12):1060-2
pubmed: 18036039
Ren Fail. 2013 Jul;35(6):825-9
pubmed: 23692545
Neuroimage. 2020 Mar;208:116459
pubmed: 31837471
PLoS One. 2011;6(9):e25227
pubmed: 21966463
Urol Res. 2000 Jun;28(3):159-66
pubmed: 10929424
Exp Mol Pathol. 2020 Oct;116:104493
pubmed: 32659237
J Clin Endocrinol Metab. 2013 Sep;98(9):3839-47
pubmed: 23864702
Nefrologia. 2007;27(6):694-703
pubmed: 18336098
Urol Int. 2013;91(2):220-6
pubmed: 23363559
Urol Res. 2007 Oct;35(5):219-24
pubmed: 17628794
Urol Int. 2005;75(3):264-8
pubmed: 16215317
Genet Test Mol Biomarkers. 2018 Mar;22(3):187-192
pubmed: 29489416
J Clin Endocrinol Metab. 2019 Oct 1;104(10):4539-4551
pubmed: 31074789